Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales-Reference-Cited by-同舟云学术

Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales

Published:2022-03-24 Issue:1 Volume:14 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Rodriguez-Conde Sara¹,Inman Sophie²,Lindo Viv²,Amery Leanne³,Tang Alison⁴,Okorji-Obike Uche⁵,Du Wenjuan⁶,Bosch Berend-Jan⁶^ORCID,Wichgers Schreur Paul J.⁷,Kortekaas Jeroen⁸,Sola Isabel⁹,Enjuanes Luis⁹,Kerry Laura⁵,Mahal Katharina⁵,Hulley Martyn⁴,Daramola Olalekan¹

Affiliation:

1. Cell Culture & Fermentation Sciences, BioPharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

2. Analytical Sciences, BioPharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

3. Late-Stage Formulation Sciences, BioPharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

4. Purification Process Sciences, BioPharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

5. Analytical Sciences, Bioassay Biosafety and Impurities, BioPharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

6. Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands

7. Department of Virology and Molecular Biology, Wageningen Bioveterinary Research, Lelystad, The Netherlands

8. Boehringer Ingelheim Animal Health, Saint Priest, France

9. Department of Molecular and Cell Biology, National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid, Spain

Funder

Zoonotic Anticipation and Preparedness Initiative

Innovative Medicines Initiative (IMI

European Federation of Pharmaceutical Industries and Associations

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link